

Original Research



Efficacy of nobiletin in improving hypercholesterolemia and nonalcoholic fatty liver disease in high-cholesterol diet-fed mice

Young-Je Kim ¹, Dae Seong Yoon ², and Un Ju Jung ^{2§}

¹Department of Food Science and Nutrition, Kyungpook National University, Daegu 41566, Korea

²Department of Food Science and Nutrition, Pukyong National University, Busan 48513, Korea

OPEN ACCESS

Received: Nov 25, 2020

Revised: Feb 5, 2021

Accepted: Feb 16, 2021

§Corresponding Author:

Un Ju Jung

Department of Food Science and Nutrition,
Pukyong National University, 45 Yongso-ro,
Nam-gu, Busan 48513, Korea.

Tel. +82-51-629-5850

Fax. +82-51-629-5842

E-mail. jungunju@naver.com

jungunju@pknu.ac.kr


©2021 The Korean Nutrition Society and the
Korean Society of Community Nutrition

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.


ORCID iDs

Young-Je Kim 

<https://orcid.org/0000-0003-2608-1649>

Dae Seong Yoon 

<https://orcid.org/0000-0002-3114-4336>

Un Ju Jung 

<https://orcid.org/0000-0002-5441-460X>

Funding

This work was supported by a Research Grant
of Pukyong National University (2019).

Conflict of Interest

The authors declare no potential conflicts of
interests.

ABSTRACT

BACKGROUND/OBJECTIVES: Nobiletin (NOB), a citrus flavonoid, is reported to have beneficial effects on cardiovascular and metabolic health. However, there is limited research investigating the effect of long-term supplementation with low-dose NOB on high-cholesterol diet (HCD)-induced hypercholesterolemia and non-obese nonalcoholic fatty liver disease (NAFLD). Therefore, we investigated the influence of NOB on hypercholesterolemia and NAFLD in HCD-fed mice.

SUBJECTS/METHODS: C57BL/6J mice were fed a normal diet (ND) or HCD (35 kcal% fat, 1.25% cholesterol, 0.5% cholic acid) with or without NOB (0.02%) for 20 weeks.

RESULTS: HCD feeding markedly reduced the final body weight compared to ND feeding, with no apparent energy intake differences. NOB supplementation suppressed HCD-induced weight loss without altering energy intake. Moreover, NOB significantly decreased the total cholesterol (TC) levels and the low-density lipoprotein (LDL)/very-LDL-cholesterol to TC ratio, and increased the high-density lipoprotein-cholesterol/TC ratio in plasma, compared to those for HCD feeding alone. The plasma levels of inflammatory and atherosclerosis markers (C-reactive protein, oxidized LDL, interleukin [IL]-1 β , IL-6, and plasminogen activator inhibitor-1) were significantly lower, whereas those of anti-atherogenic adiponectin and paraoxonase were higher in the NOB-supplemented group than in the HCD control group. Furthermore, NOB significantly decreased liver weight, hepatic cholesterol and triglyceride contents, and lipid droplet accumulation by inhibiting messenger RNA expression of hepatic genes and activity levels of cholesterol synthesis-, esterification-, and fatty acid synthesis-associated enzymes, concomitantly enhancing fatty acid oxidation-related gene expression and enzyme activities. Dietary NOB supplementation may protect against hypercholesterolemia and NAFLD via regulation of hepatic lipid metabolism in HCD-fed mice; these effects are associated with the amelioration of inflammation and reductions in the levels of atherosclerosis-associated cardiovascular markers.

CONCLUSIONS: The present study suggests that NOB may serve as a potential therapeutic agent for the treatment of HCD-induced hypercholesterolemia and NAFLD.

Keywords: Nobiletin; hypercholesterolemia; non-alcoholic fatty liver disease; inflammation

Author Contributions

Conceptualization: Jung UJ; Formal analysis: Kim YJ; Funding Acquisition: Jung UJ; Investigation: Kim YJ; Methodology: Jung UJ; Supervision: Jung UJ; Writing - original draft: Jung UJ; Writing - review & editing: Jung UJ, Kim YJ, Yoon DS.

INTRODUCTION

Cholesterol is necessary for good health. However, hypercholesterolemia, defined as an abnormally increased level of cholesterol in blood, is a serious health condition. It is a major risk factor for the development of cardiovascular diseases, such as atherosclerosis and its complications. In addition, many studies suggest an association of dietary cholesterol intake with the risk of nonalcoholic fatty liver disease (NAFLD), a broad spectrum of liver diseases, ranging from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and liver cancer [1-5]. Although most patients with NAFLD are obese, NAFLD is also observed in non-obese subjects [1]. Epidemiologic studies suggest that a high-cholesterol diet (HCD) is a critical factor in non-obese NAFLD [1,2]. In a small Italy-based study, normal-weight patients with steatohepatitis showed higher cholesterol consumption than that of BMI-matched healthy controls [3]. Yasutake *et al.* [1] also reported that cholesterol intake in non-obese NAFLD patients was notably high compared to that in obese NAFLD patients and healthy volunteers, although dietary intake levels of total energy, fat, and carbohydrate were not excessive in the non-obese patients. Animal studies using cholesterol-rich diets support the results obtained in non-obese NAFLD patients [4,5]. C57BL/6J mice fed an HCD (containing 1.25% cholesterol and 0.5% cholic acid) developed progressive steatosis, inflammation, and fibrosis without obesity [4]. Recently, Tu *et al.* [5] also demonstrated that HCD-induced non-obese NAFLD might be distinct from obese NAFLD occurring as a consequence of metabolic syndrome. Moreover, patients with NAFLD are at an increased risk of cardiovascular disease, and NAFLD is proposed as an independent risk factor for cardiovascular disease [6,7].

Nobiletin (5,6,7,8,3',4'-hexamethoxyflavone, NOB) is a flavonoid present in the peel of citrus fruits such as *Citrus depressa* (shiikuwasa), *Citrus sinensis* (oranges), and *Citrus limon* (lemons) [8]. It has been reported that NOB has various pharmacological activities, such as anti-inflammation, antioxidation, anti-cancer, and neuroprotection effects [8]. Hepatoprotective, cardioprotective, and metabolically beneficial properties of NOB have also been demonstrated [9-11]. *In vitro*, NOB inhibited hepatic lipogenesis in HepG2 hepatocytes via modulation of the AMPK signaling pathway and exerted cardiovascular protective effects by preventing the oxidized low-density lipoprotein (oxLDL)-mediated expression of Tissue Factor in human endothelial cells through the inhibition of nuclear factor- κ B [9,10]. *In vivo* studies support a link between NOB and anti-metabolic effects [11-13]. NOB (0.1% or 0.3%) prevented dyslipidemia, hepatic triglyceride accumulation, and atherosclerotic lesion development in high-fat diet (HFD, 42 kcal% fat, no added cholesterol or cholic acid)-fed low-density lipoprotein receptor (*Ldlr*)-/- mice [11]. In other research conducted in their laboratory, *Ldlr*-/- mice were initially fed an HFD (42 kcal% fat, 0.2% cholesterol) over 12 weeks and received an HFD supplemented with 0.3% NOB for the subsequent 12 weeks [12]. NOB attenuated obesity, insulin resistance, hyperlipidemia, and hepatic steatosis, and it favorably altered aortic sinus atherosclerotic plaque composition [12]. Similarly, our previous study demonstrated that NOB supplementation (0.02%, approximately 17 mg/kg body weight/day) for 16 weeks attenuated dyslipidemia, hepatic steatosis, insulin resistance, and inflammation without altering adiposity in HFD (45 kcal% fat, no added cholesterol or cholic acid)-induced obese mice [13]. However, there is limited research investigating the effect of long-term supplementation with low-dose NOB on HCD-induced hypercholesterolemia and non-obese NAFLD.

In the present study, we hypothesized that long-term supplementation with low-dose NOB might exert protective effects against HCD-induced hypercholesterolemia and non-obese

NAFLD by regulating lipogenesis and fatty acid oxidation in the liver, and these beneficial effects might be associated with the anti-inflammatory and cardiovascular protective effects of NOB. Therefore, we investigated the effects of NOB on plasma levels of lipids and inflammatory and atherosclerosis markers, as well as on hepatic morphology and lipid content in HCD-fed C57BL/6J mice. The enzyme activities and messenger RNA (mRNA) expression levels of genes involved in lipid metabolism were also evaluated. In particular, the present study focused on evaluating the effects of NOB on hepatic cholesterol metabolism, including cholesterol synthesis, esterification, and influx.

MATERIALS AND METHODS

Animals and experimental diets

Four-week-old male C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and housed under standard conditions with free access to chow and water. All animals were acclimated for 1 week before use. At 5 weeks of age, they were randomly divided into three groups ($n = 12$ in each group). The first group was fed a normal diet (ND). The second group was considered the negative control group and was fed only an HCD (D12336; Research Diets, New Brunswick, NJ, USA). The third group was fed the HCD and received dietary supplementation with NOB (0.02%). NOB was isolated from the peels of shiikuwasa (*C. depressa*) by performing methanol extraction followed by two chromatographic steps; its purity was verified by nuclear magnetic resonance and mass spectroscopy, as previously described [13]. The HCD contained 16% fat (5% soybean oil, 7.5% cocoa butter, 3.5% coconut oil; 35 kcal% fat), 1.25% cholesterol, and 0.5% cholic acid. Mice were provided access to food and water *ad libitum* during the 20-week study period. All animal procedures related to the animal studies were approved by the Ethics Committee at Kyungpook National University (approval No. KNU-2014-45).

Food consumption and body weight were measured daily and weekly, respectively. At the end of the experimental period, the mice were anesthetized with isoflurane (5 mg/kg body weight; Baxter, USA) following a 12-h fast. Blood samples were collected from the inferior vena cava into a heparin-coated tube for plasma biochemical analysis. Liver and white adipose tissue were excised, weighed, and snap-frozen in liquid nitrogen. All tissues were stored at -70°C until further analyses.

Plasma biochemical analysis

The plasma levels of total cholesterol (TC) and triglycerides were determined using enzymatic kits (Asan, Seoul, Republic of Korea). The levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL)/very-LDL (VLDL) in plasma were measured using an HDL and LDL/VLDL-cholesterol assay kit (Abcam, Cambridge, MA, UK). Plasma C-reactive protein (CRP; R&D systems, Minneapolis, NE, USA) and oxLDL (MyBioSource, San Diego, CA, USA) levels were assessed using commercial assay kits. Plasma levels of adipocytokines (adiponectin, plasminogen activator inhibitor-1 [PAI-1], interleukin [IL]-1 β , and IL-6) were determined using a multiplex detection kit (Bio-Rad, Hercules, CA, USA).

Hepatic lipid analyses

Hepatic lipids were extracted as previously described [14], and dried lipid residues were dissolved in 1 mL of ethanol for triglyceride and cholesterol assays. Triton X-100 and a sodium cholate solution in distilled water were added to 200 μL of the dissolved lipid solution for

emulsification. The hepatic triglyceride and cholesterol contents were analyzed with the same enzymatic kit used for the plasma analysis.

Enzyme analyses

Cytosolic, mitochondrial, and microsomal fractions were prepared from liver homogenate using differential centrifugation to determine the activities of lipid-regulating enzymes. The 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase and acyl-CoA:cholesterol acyltransferase (ACAT) activities in the microsomal fraction were determined by a procedure adapted from those of Shapiro *et al.* [15] and Erickson *et al.* [16], respectively. Cytosolic fatty acid synthase (FAS) activity was measured by monitoring the malonyl CoA-dependent oxidation of NADPH based on the absorbance of the samples at 340 nm [17]. Mitochondrial carnitine palmitoyltransferase (CPT) activity was determined using a spectrophotometric assay that measured the CoA-SH release from palmitoyl-CoA [18]. Mitochondrial fatty acid β -oxidation was measured by monitoring the reduction of NAD⁺ to NADH in the presence of palmitoyl-CoA by applying a previously described method [19]. Protein concentration in each fraction was estimated by using the Bradford method [20]. Plasma paraoxonase activity was spectrophotometrically assayed using the method described by Mackness *et al.* [21].

Isolation of total RNA and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analysis

Total RNA was isolated from liver using TRIZOL reagent (Invitrogen Life Technologies, Grand Island, NY, USA). RNA integrity for each sample was evaluated by using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). The complementary DNA was synthesized using 1 μ g RNA and a QuantiTect[®] reverse transcription kit (Qiagen, Hilden, Germany). qRT-PCR was carried out on a CFX96TM real-time system (Bio-Rad) using the SYBR Green qRT-PCR kit (Qiagen). The mRNA levels of each target gene were normalized to that of GAPDH mRNA. The relative gene expression levels were calculated according to the $2^{-\Delta\Delta CT}$ method.

Histological analysis

Liver tissues were fixed in 10% formalin solution, dehydrated, embedded in paraffin, and cut into 4- μ m-thick sections. Cross-sections of these tissues were stained with hematoxylin and eosin. Stained areas were viewed using an optical microscope (Nikon, Tokyo, Japan) and a magnifying power of 200 \times .

Statistical analysis

The results are presented as mean \pm SE values. Differences between 2 groups (ND vs. HCD and HCD vs. HCD + NOB) were determined using Student's t-test. Initially, to determine whether there is statistical evidence that the diet-associated means are significantly different, Student's t-test was applied to the means of the ND and HCD groups. Also, in order to determine the effect of NOB on HCD-induced hypercholesterolemia and NAFLD, the Student's t-test was used to compare the mean values of HCD-fed mice receiving or not receiving NOB supplementation. Test result *P*-values of less than 0.05 were considered statistically significant. Statistical analysis was performed using SPSS statistical software (version 11.0; SPSS Inc., Chicago, IL, USA).

RESULTS

NOB suppresses HCD-induced weight loss

HCD-fed mice showed significantly lower food intake, body weight, fat mass (total weight of all white adipose tissue depots including epididymal, perirenal, retroperitoneal, mesenteric, subcutaneous, and interscapular white adipose tissue), and food efficiency ratio (FER) compared to those of ND-fed mice. However, there was no significant difference in energy intake between the ND and HCD groups (**Fig. 1**). In HCD-fed mice, dietary NOB supplementation did not affect the amount of food consumed, energy intake, and fat mass (**Fig. 1A, B, and E**). However, NOB tended to increase final body weight ($P = 0.51$), and NOB-supplemented mice showed significantly increased body weight gain and FER compared to HCD control mice (**Fig. 1C, D, and F**).

NOB decreases the levels of circulating cholesterol, CRP, oxLDL, inflammatory markers, and PAI-1 but increases the circulating adiponectin level and paraoxonase activity

Over 20 weeks, plasma TC levels were significantly increased in HCD-fed mice compared to those of the ND-fed mice (**Fig. 2A**). In addition, mice fed with HCD showed a significantly higher ratio of plasma LDL/VLDL-cholesterol to TC, and the HDL-cholesterol/TC ratio and triglyceride levels were lower in the HCD group than those in the ND group (**Fig. 2B and C**). In HCD-fed mice, NOB supplementation significantly lowered the plasma TC levels compared to the HCD control group level (**Fig. 2A**). Moreover, the mean ratio of plasma LDL/VLDL-cholesterol to TC in NOB-supplemented mice was significantly lower than that in HCD control mice, whereas NOB supplementation markedly increased the HDL-cholesterol/TC ratio but did not significantly affect the plasma triglyceride level (**Fig. 2B and C**).




Fig. 1. Effect of NOB on food intake (A), energy intake (B), body weight (C, D), fat mass (E), and FER (F) in HCD-fed mice. Values are presented as mean \pm SE ($n = 12$). Values are significantly different between the groups, according to Student's *t*-test.

ND, normal diet; HCD, high-cholesterol diet (35 kcal% fat, 1.25% cholesterol, 0.5% cholic acid); HCD + NOB, high-cholesterol diet plus nobiletin (0.02%); FER, food efficiency ratio.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ND vs. HCD; # $P < 0.05$, ## $P < 0.01$, HCD vs. HCD + NOB.




Fig. 2. Effect of nobiletin on plasma levels of TC (A), ratios of LDL/VLDL- and HDL-cholesterol to TC (B), and plasma levels of triglyceride (C), CRP (D), oxLDL (E), paraoxonase (F), and adipocytokines (G, H) in HCD-fed mice. Values are presented as mean ± SE (n = 12). Values are significantly different between the groups, according to Student's t-test.

TC, total cholesterol; ND, normal diet; HCD, high-cholesterol diet (35 kcal% fat, 1.25% cholesterol, 0.5% cholic acid); HCD + NOB, high-cholesterol diet plus nobiletin (0.02%); LDL/VLDL-C, low-density lipoprotein/very low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; CRP, C-reactive protein; oxLDL, oxidized low-density lipoprotein; IL, interleukin; PAI-1, plasminogen activator inhibitor-1.

*P < 0.05, **P < 0.01, ***P < 0.001, ND vs. HCD; #P < 0.05, ##P < 0.01, ###P < 0.001, HCD vs. HCD + NOB.

HCD feeding also caused significant increases in the levels of plasma markers of inflammation and atherosclerosis, such as CRP, oxLDL, IL-1β, IL-6, and PAI-1, compared to those from ND feeding. Conversely, the activity of plasma paraoxonase, an HDL-associated enzyme exhibiting potentially anti-atherogenic properties, was markedly lowered in HCD-fed mice compared to that in ND-fed mice (Fig. 2D-H). Dietary NOB supplementation normalized the HCD-induced changes to these markers (Fig. 2D-H). Furthermore, plasma adiponectin levels were significantly lower in HCD-fed mice than those in ND-fed mice, and NOB supplementation markedly increased the plasma adiponectin levels compared to those in the HCD group (Fig. 2H).

NOB decreases liver weight and hepatic lipid accumulation

Hepatic cholesterol and triglyceride contents, as well as liver weight, were higher in HCD-fed mice than in ND-fed mice (Fig. 3A and B). In contrast, NOB-supplemented mice showed significantly reduced liver weight and hepatic cholesterol and triglyceride contents compared to those of the HCD control group. Morphological analyses of liver tissues also indicated that lipid droplet accumulation was more pronounced in HCD-fed mice than in ND-fed mice; however, NOB supplementation markedly decreased hepatic lipid accumulation compared to that in the HCD-fed mice (Fig. 3C). Overall, dietary NOB supplementation might ameliorate HCD-mediated hepatic steatosis in mice.

NOB regulates expressions of lipid metabolism-related genes and enzyme activity in liver

To determine how NOB ameliorated HCD-induced hepatic steatosis, we examined the mRNA expression levels of genes and the activities of enzymes involved in hepatic cholesterol and triglyceride accumulation. HCD feeding led to a significant decrease in the mRNA expression of hepatic genes involved in cholesterol synthesis, esterification, and influx (*Srebp2*, *Hmgcr*,




Fig. 3. Effect of NOB on liver weight (A), hepatic lipid content (B), liver morphology (C), expression of hepatic lipid metabolism-related genes (D, E), and activities of hepatic lipid metabolism-related enzymes (F) in HCD-fed mice. (A, B, D-F) Values are presented as mean \pm SE (n = 12). Values are significantly different between the groups, according to the Student's t-test. (C) Representative photomicrographs of livers are shown at 200 \times magnification. ND, normal diet; HCD, high-cholesterol diet (35 kcal% fat, 1.25% cholesterol, 0.5% cholic acid); HCD + NOB, high-cholesterol diet plus nobiletin (0.02%); mRNA, messenger RNA; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl-CoA reductase; ACAT, acyl-CoA:cholesterol acyltransferase; FAS, fatty acid synthase; CPT, carnitine palmitoyltransferase.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ND vs. HCD; # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$, HCD vs. HCD + NOB.

Acat1, *Acat2*, *Ldlr*) compared to those in the ND group (Fig. 3D). In addition, the mRNA expression levels of hepatic *Srebf1*, a key lipogenic transcription factor, and its target gene *Fas* were higher in the HCD group, whereas those of hepatic *Ppara*, a major transcription factor involved in fatty acid β -oxidation, were lower in the HCD group compared with those in the ND group (Fig. 3E). Mice that received NOB supplementation showed significantly decreased mRNA expression of genes involved in cholesterol synthesis and esterification (*Srebp2*, *Hmgcr*, *Acat2*) as well as in lipogenesis (*Srebf1* and *Fas*) in the liver, along with the upregulation of hepatic *Ppara* mRNA expression, compared to the expression levels in the HCD negative control group (Fig. 3D and E). Similar to the trends observed in gene expression, the activities of HMG-CoA reductase, ACAT, CPT, and β -oxidation were significantly lower in the HCD group than in the ND group (Fig. 3F). In contrast, hepatic FAS activity was significantly higher in the HCD group than in the ND group. In HCD-fed mice, NOB supplementation significantly decreased the activities of hepatic HMG-CoA reductase, ACAT, and FAS (Fig. 3F). Moreover, NOB significantly increased CPT and β -oxidation activities compared to those in the HCD group (Fig. 3F).

DISCUSSION

The HCD-fed C57BL/6J mouse utilized in the present study is a commonly used animal model of hypercholesterolemia and atherosclerosis [22]. Unlike most mouse strains resistant to developing hypercholesterolemia and atherosclerosis, even on an HCD, the HCD-fed C57BL/6 mouse exhibits an approximate 50% reduction in the plasma HDL-cholesterol level [22]. Similarly, in the present study, HCD-fed C57BL/6J mice demonstrated significantly higher TC and LDL/VLDL-cholesterol to TC ratio values and a lower HDL-cholesterol/TC ratio. Moreover, HCD-fed mice developed NAFLD and showed a significantly lower weight gain compared to that of ND-fed mice, although the daily energy intake was similar in both groups. These results are consistent with those of a previous study [4], which demonstrated that HCD-fed mice are not obese but show hepatomegaly and NAFLD. Since an atherogenic diet high in cholesterol and cholic acid can induce toxicity symptoms like weight loss [23], it seems that the loss of body weight and fat mass observed in HCD group may be the result of a toxic effect and dietary growth inhibition.

The present study showed that dietary supplementation with low-dose NOB (0.02%) for 20 weeks suppressed HCD-induced weight loss and decreased TC plasma levels in mice fed an HCD. In addition, NOB markedly decreased the ratio of plasma LDL/VLDL-cholesterol to TC but increased the HDL-cholesterol/TC ratio compared to that of the HCD control group. Similar to our results, NOB was shown to decrease the circulating levels of VLDL and LDL *in vitro* [24], and HFD-fed aged mice supplemented with NOB (0.1%) showed reductions in serum LDL/VLDL-cholesterol levels and the LDL/HDL ratio [25]. Recently, Morrow *et al.* [26] also demonstrated that plasma TC and LDL-cholesterol levels were decreased by NOB (0.3%) in C57BL/6J mice fed an HFD (42 kcal% fat, 0.2% cholesterol).

The beneficial effects of NOB on HCD-induced hypercholesterolemia may contribute to protection against cardiovascular disease. Hypercholesterolemia is generally associated with increased levels of oxLDL [27], which leads to the activation of pro-inflammatory and atherogenic cytokines, thereby contributing to the progression of atherogenesis [28]. Plasma oxLDL is considered a strong predictor of atherosclerotic cardiovascular disease [29]. In addition to affecting oxLDL, NOB diminishes the HCD-mediated upregulation of circulating inflammatory markers, like CRP, IL-6, and IL-1 β , which have been shown to independently predict cardiovascular disease [30-34]. In particular, circulating CRP is stable over long periods, has no diurnal variation, and has been suggested to be a stronger predictor of cardiovascular events than the LDL-cholesterol level [30,31]. Taken together, NOB might exert cardiovascular protective effects by preventing oxLDL formation and decreasing the plasma levels of the pro-inflammatory and atherosclerosis markers CRP, IL-6, and IL-1 β . These findings are supported by a decreased level of PAI-1, increased level of adiponectin, and increased activity of paraoxonase, an HDL-associated enzyme that protects against LDL oxidation, observed in the plasma of NOB-supplemented mice. A high level of PAI-1, a major regulator of the fibrinolytic system, is associated with an increased cardiovascular risk of arterial and thrombotic disease [35], whereas circulating adiponectin exerts protection against cardiovascular disease [36]. In animal studies using either pharmacological or genetic approaches, inhibition of PAI-1 is suggested to be a therapeutic option for cardiovascular protection, and the elevation of plasma adiponectin alleviates atherosclerosis [36,37]. In addition, several studies have demonstrated a protective role of paraoxonase in cardiovascular diseases, such as atherosclerosis and ischemic stroke [38,39].

The liver is the principal organ for cholesterol homeostasis. Cholesterol is synthesized primarily in the liver and transported to other tissues via the blood in the form of lipoproteins. Hepatic cholesterol synthesis, storage by esterification, uptake, and excretion have important roles in whole-body cholesterol homeostasis, and losing control of any of these processes results in hypercholesterolemia and increases the risk for cardiovascular disease [40]. HMG-CoA reductase is responsible for cholesterol synthesis in the liver [40], and ACAT converts cholesterol into its storage form, cholesteryl esters [40]. In mammals, there are two isoforms of ACAT; *Acat1* is a ubiquitous gene, whereas *Acat2* is primarily located in liver and intestine. The hepatic *Acat2* synthesizes cholesteryl esters for incorporation into VLDL and provides cholesteryl ester for the formation of cytoplasmic lipid droplets, a storage method when liver cholesterol is abundant [41]. Deletion of liver-specific *Acat2* results in resistance to hypercholesterolemia and hepatic lipid accumulation induced by a diet high in fat and cholesterol in mice [42], while *Acat1*-deficient mice showed no apparent effects on plasma cholesterol level and cholesterol esterification activity [43], indicating a specialized role of *Acat2* in cholesteryl ester synthesis in the liver. Interestingly, in the present study, NOB significantly downregulated the hepatic mRNA expression of *Hmgcr* and *Acat2*, although it did not alter hepatic *Acat1* mRNA expression. Moreover, the mRNA expression of hepatic *Srebp2*, a primary transcriptional factor for the activation of *Hmgcr* [44], was downregulated, and NOB inhibited the corresponding enzyme activities. Therefore, it seems possible that the inhibition of cholesterol synthesis and esterification might reduce the availability of hepatic cholesterol for VLDL formation and contribute to decreased secretion of VLDL, which consequently ameliorates HCD-induced hypercholesterolemia.

Furthermore, reduced cholesterol synthesis and esterification through the downregulation of hepatic *Srebp2*, *Hmgcr*, and *Acat2* could contribute to the attenuation of HCD-induced NAFLD observed in NOB-supplemented mice, since disturbed hepatic cholesterol homeostasis is relevant to the pathogenesis of NAFLD [45]. Expression of hepatic *Hmgcr* and *Srebp2* is increased in NAFLD patients [3], and liver-specific inhibition of *Acat2* with antisense oligonucleotides decreases the accumulation of neutral lipids (cholesteryl ester and triglyceride) in HCD-fed mice [46]. Another potential mechanism underlying the protective effects of NOB against NAFLD might be associated with decreased *de novo* lipogenesis and increased fatty acid oxidation in the liver. In a previous study, feeding C57BL/6J mice with an HCD (1.25% cholesterol, 0.5% cholic acid) not only upregulated the hepatic mRNA expression of genes involved in *de novo* lipogenesis (*Srebf1* and *Fas*) but also downregulated the hepatic mRNA expression of genes associated with the mitochondrial fatty acid oxidation pathway (*Ppara* and *Cpt1a*), contributing to the pathogenesis of non-obese NAFLD [6]. Similarly, the present study demonstrated markedly increased expression and activity levels of *de novo* fatty acid synthesis-related genes and enzymes, respectively, and decreased the expression and activities of fatty acid oxidation-related genes and enzymes, respectively, in the liver in response to the HCD. Notably, NOB supplementation normalized these HCD-induced changes in the expression and activities of these fatty acid synthesis- and β -oxidation-related genes and enzymes, respectively, in the liver. These results indicate that the protective effects of NOB against HCD-induced NAFLD might be partly due to decreased lipogenesis and increased fatty acid oxidation in the liver, along with the regulation of cholesterol metabolism.

In a previous study, we demonstrated that NOB can protect against dyslipidemia and NAFLD in HFD (no added cholesterol or cholic acid)-induced obese mice [13]. However, the mechanisms underlying its protective effects against HCD (containing high-cholesterol and cholic acid)-related metabolic dysfunction, such as hypercholesterolemia and non-obese

NAFLD, remain unclear. Therefore, the present study focused on evaluating the effects of NOB on hepatic cholesterol metabolism (including cholesterol synthesis, esterification, and influx) and hypercholesterolemia-associated plasma biomarkers (including CRP, oxLDL, IL-1 β , IL-6, PAI-1, adiponectin and paraoxonase) in HCD-fed C57BL/6J mice, a commonly used animal model of hypercholesterolemia and atherosclerosis [22]. Our novel findings reveal that NOB could protect against hypercholesterolemia and non-obese NAFLD by inhibiting mRNA expression of hepatic genes and activities of cholesterol synthesis and esterification, along with inhibition of fatty acid synthesis and promotion of fatty acid oxidation. Also, these effects were associated with the amelioration of inflammation and the regulation of plasma levels of atherosclerosis-associated cardiovascular markers.

In conclusion, the present study demonstrates, for the first time, that long-term supplementation of low-dose NOB might attenuate HCD-induced hypercholesterolemia and NAFLD by regulating cholesterol synthesis and esterification, *de novo* lipogenesis, and fatty acid oxidation in the liver. In addition, NOB supplementation can decrease pro-inflammatory and atherosclerosis marker levels and increase adiponectin level and paraoxonase activity in plasma, suggesting that it might exert cardioprotective effects. Taken together, the results support the suggestion that NOB can potentially ameliorate hypercholesterolemia, cardiovascular disease, and NAFLD.

ACKNOWLEDGMENTS

The authors are thankful to Je Tae Woo, who kindly supplied the nobiletin.

REFERENCES

1. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. *Scand J Gastroenterol* 2009;44:471-7.
[PUBMED](#) | [CROSSREF](#)
2. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Fagà E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* 2003;37:909-16.
[PUBMED](#) | [CROSSREF](#)
3. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. *Cell Metab* 2012;15:665-74.
[PUBMED](#) | [CROSSREF](#)
4. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. *Hepatology* 2007;46:1392-403.
[PUBMED](#) | [CROSSREF](#)
5. Tu LN, Showalter MR, Cajka T, Fan S, Pillai VV, Fiehn O, Selvaraj V. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. *Sci Rep* 2017;7:6120.
[PUBMED](#) | [CROSSREF](#)
6. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. *Diabetes* 2005;54:3541-6.
[CROSSREF](#)
7. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. *World J Gastroenterol* 2007;13:1579-84.
[PUBMED](#) | [CROSSREF](#)

8. Huang H, Li L, Shi W, Liu H, Yang J, Yuan X, Wu L. The multifunctional effects of nobiletin and its metabolites *in vivo* and *in vitro*. *Evid Based Complement Alternat Med* 2016;2016:2918796.
[PUBMED](#) | [CROSSREF](#)
9. Yuk T, Kim Y, Yang J, Sung J, Jeong HS, Lee J. Nobiletin inhibits hepatic lipogenesis via activation of AMP-activated protein kinase. *Evid Based Complement Alternat Med* 2018;2018:7420265.
[PUBMED](#) | [CROSSREF](#)
10. Cirillo P, Conte S, Cimmino G, Pellegrino G, Ziviello F, Barra G, Sasso FC, Borgia F, De Palma R, Trimarco B. Nobiletin inhibits oxidized-LDL mediated expression of tissue factor in human endothelial cells through inhibition of NF- κ B. *Biochem Pharmacol* 2017;128:26-33.
[PUBMED](#) | [CROSSREF](#)
11. Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. *Diabetes* 2011;60:1446-57.
[PUBMED](#) | [CROSSREF](#)
12. Burke AC, Sutherland BG, Telford DE, Morrow MR, Sawyez CG, Edwards JY, Drangova M, Huff MW. Intervention with citrus flavonoids reverses obesity and improves metabolic syndrome and atherosclerosis in obese *Ldlr*^{-/-} mice. *J Lipid Res* 2018;59:1714-28.
[PUBMED](#) | [CROSSREF](#)
13. Kim YJ, Choi MS, Woo JT, Jeong MJ, Kim SR, Jung UJ. Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity. *Mol Nutr Food Res* 2017;61:1600889.
[PUBMED](#) | [CROSSREF](#)
14. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 1957;226:497-509.
[PUBMED](#) | [CROSSREF](#)
15. Shapiro DJ, Nordstrom JL, Mitschelen JJ, Rodwell VW, Schimke RT. Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. *Biochim Biophys Acta* 1974;370:369-77.
[PUBMED](#) | [CROSSREF](#)
16. Erickson SK, Shrewsbury MA, Brooks C, Meyer DJ. Rat liver acyl-coenzyme A:cholesterol acyltransferase: its regulation *in vivo* and some of its properties *in vitro*. *J Lipid Res* 1980;21:930-41.
[PUBMED](#) | [CROSSREF](#)
17. Nepokroeff CM, Lakshmanan MR, Porter JW. Fatty-acid synthase from rat liver. *Methods Enzymol* 1975;35:37-44.
[PUBMED](#) | [CROSSREF](#)
18. Markwell MA, McGroarty EJ, Bieber LL, Tolbert NE. The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. A new peroxisomal enzyme. *J Biol Chem* 1973;248:3426-32.
[PUBMED](#) | [CROSSREF](#)
19. Lazarow PB. Assay of peroxisomal β -oxidation of fatty acids. *Methods Enzymol* 1981;72:315-9.
[PUBMED](#) | [CROSSREF](#)
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248-54.
[PUBMED](#) | [CROSSREF](#)
21. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett* 1991;286:152-4.
[PUBMED](#) | [CROSSREF](#)
22. Paigen B, Mitchell D, Reue K, Morrow A, Lusa AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. *Proc Natl Acad Sci U S A* 1987;84:3763-7.
[PUBMED](#) | [CROSSREF](#)
23. Jawień J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. *J Physiol Pharmacol* 2004;55:503-17.
[PUBMED](#)
24. Whitman SC, Kurowska EM, Manthey JA, Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. *Atherosclerosis* 2005;178:25-32.
[PUBMED](#) | [CROSSREF](#)
25. Nohara K, Nemkov T, D'Alessandro A, Yoo SH, Chen Z. Coordinate regulation of cholesterol and bile acid metabolism by the clock modifier nobiletin in metabolically challenged old mice. *Int J Mol Sci* 2019;20:4281.
[PUBMED](#) | [CROSSREF](#)

26. Morrow NM, Burke AC, Samsouard JP, Seigel KE, Wang A, Telford DE, Sutherland BG, O'Dwyer C, Steinberg GR, Fullerton MD, et al. The citrus flavonoid nobiletin confers protection from metabolic dysregulation in high-fat-fed mice independent of AMPK. *J Lipid Res* 2020;61:387-402.
[PUBMED](#) | [CROSSREF](#)
27. Owens AP, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. 2012;122:558-68.
[PUBMED](#) | [CROSSREF](#)
28. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. *J Lipid Res* 2004;45:993-1007.
[PUBMED](#) | [CROSSREF](#)
29. Meisinger C, Baumert J, Khuseynova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. *Circulation* 2005;112:651-7.
[PUBMED](#) | [CROSSREF](#)
30. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? *Ann Intern Med* 2002;136:529-33.
[PUBMED](#) | [CROSSREF](#)
31. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002;347:1557-65.
[PUBMED](#) | [CROSSREF](#)
32. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. *Biochem J* 1995;310:143-8.
[PUBMED](#) | [CROSSREF](#)
33. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? *Atherosclerosis* 2000;148:209-14.
[PUBMED](#) | [CROSSREF](#)
34. Weinhold B, R  ther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. *Biochem J* 1997;327:425-9.
[PUBMED](#) | [CROSSREF](#)
35. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. *Atherosclerosis* 1992;95:105-17.
[PUBMED](#) | [CROSSREF](#)
36. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. *Br J Pharmacol* 2012;165:574-90.
[PUBMED](#) | [CROSSREF](#)
37. Baluta MM, Vintila MM. PAI-1 inhibition - another therapeutic option for cardiovascular protection. *Maedica (Bucur)* 2015;10:147-52.
[PUBMED](#)
38. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. *J Biol Chem* 2006;281:29491-500.
[PUBMED](#) | [CROSSREF](#)
39. Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. *N Am J Med Sci* 2012;4:523-32.
[PUBMED](#) | [CROSSREF](#)
40. Trapani L, Segatto M, Pallottini V. Regulation and deregulation of cholesterol homeostasis: the liver as a metabolic "power station". *World J Hepatol* 2012;4:184-90.
[PUBMED](#) | [CROSSREF](#)
41. Parini P, Davis M, Lada AT, Erickson SK, Wright TL, Gustafsson U, Sahlin S, Einarsson C, Eriksson M, Angelin B, et al. *ACAT2* is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. *Circulation* 2004;110:2017-23.
[PUBMED](#) | [CROSSREF](#)
42. Zhang J, Kelley KL, Marshall SM, Davis MA, Wilson MD, Sawyer JK, Farese RV Jr, Brown JM, Rudel LL. Tissue-specific knockouts of *ACAT2* reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. *J Lipid Res* 2012;53:1144-52.
[PUBMED](#) | [CROSSREF](#)

43. Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, Pitas RE, McGuire J, Herz J, Farese RV Jr. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. *Proc Natl Acad Sci U S A* 1996;93:14041-6.
[PUBMED](#) | [CROSSREF](#)
44. Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). *J Biol Chem* 2013;288:18707-15.
[PUBMED](#) | [CROSSREF](#)
45. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. *Biochim Biophys Acta* 2015;1852:1765-78.
[PUBMED](#) | [CROSSREF](#)
46. Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, Wilson MD, Willingham MC, Rudel LL. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (*ACAT2*) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. *J Biol Chem* 2010;285:14267-74.
[PUBMED](#) | [CROSSREF](#)